Free Trial

iTeos Therapeutics (ITOS) Competitors

iTeos Therapeutics logo
$10.16 +0.16 (+1.60%)
Closing price 04:00 PM Eastern
Extended Trading
$10.14 -0.02 (-0.16%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ITOS vs. EWTX, SDGR, BHVN, ETNB, ANIP, JANX, EVO, MESO, VERA, and OCUL

Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), Evotec (EVO), Mesoblast (MESO), Vera Therapeutics (VERA), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

iTeos Therapeutics vs. Its Competitors

Edgewise Therapeutics (NASDAQ:EWTX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Edgewise Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

In the previous week, Edgewise Therapeutics had 18 more articles in the media than iTeos Therapeutics. MarketBeat recorded 19 mentions for Edgewise Therapeutics and 1 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.93 beat Edgewise Therapeutics' score of 0.52 indicating that iTeos Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edgewise Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iTeos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edgewise Therapeutics has higher earnings, but lower revenue than iTeos Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.39
iTeos Therapeutics$35M11.11-$134.41M-$3.04-3.34

Edgewise Therapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 207.46%. iTeos Therapeutics has a consensus target price of $15.86, suggesting a potential upside of 56.07%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Edgewise Therapeutics is more favorable than iTeos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
iTeos Therapeutics
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.14

97.2% of iTeos Therapeutics shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

iTeos Therapeutics' return on equity of -21.37% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -30.95% -29.45%
iTeos Therapeutics N/A -21.37%-18.55%

Summary

Edgewise Therapeutics and iTeos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get iTeos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ITOS vs. The Competition

MetriciTeos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$382.74M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-3.3421.1726.1419.88
Price / Sales11.11278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book0.637.518.055.38
Net Income-$134.41M-$55.05M$3.15B$248.50M
7 Day Performance1.20%2.45%1.85%2.97%
1 Month Performance1.50%7.33%4.81%6.02%
1 Year Performance-29.64%5.38%34.86%20.39%

iTeos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ITOS
iTeos Therapeutics
3.2341 of 5 stars
$10.16
+1.6%
$15.86
+56.1%
-33.4%$382.74M$35M-3.3490
EWTX
Edgewise Therapeutics
2.6574 of 5 stars
$14.18
-0.8%
$39.78
+180.5%
-33.8%$1.50BN/A-9.1560News Coverage
Analyst Forecast
Analyst Revision
SDGR
Schrodinger
2.655 of 5 stars
$20.35
-0.5%
$32.80
+61.2%
+9.9%$1.50B$207.54M-7.74790
BHVN
Biohaven
2.7928 of 5 stars
$14.44
-0.2%
$58.46
+305.0%
-60.5%$1.48BN/A-1.54239
ETNB
89BIO
1.932 of 5 stars
$10.00
-0.8%
$26.43
+164.3%
+25.4%$1.47BN/A-2.9640Positive News
ANIP
ANI Pharmaceuticals
3.7226 of 5 stars
$66.03
+0.7%
$80.13
+21.3%
+0.2%$1.42B$614.38M-51.99600
JANX
Janux Therapeutics
2.3085 of 5 stars
$22.88
-3.1%
$95.25
+316.3%
-44.3%$1.40B$10.59M-16.8230
EVO
Evotec
1.6433 of 5 stars
$3.81
+1.3%
$5.93
+55.7%
-13.2%$1.34B$862.40M0.004,827Positive News
MESO
Mesoblast
2.1354 of 5 stars
$10.16
-2.7%
$18.00
+77.2%
+78.8%$1.33B$5.90M0.0080News Coverage
Gap Down
VERA
Vera Therapeutics
3.5789 of 5 stars
$21.65
+3.8%
$65.00
+200.2%
-36.6%$1.33BN/A-7.2240Positive News
OCUL
Ocular Therapeutix
3.7949 of 5 stars
$8.37
+3.0%
$17.33
+107.1%
+36.6%$1.30B$63.72M-7.28230

Related Companies and Tools


This page (NASDAQ:ITOS) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners